Secukinumab Loss of Efficacy Is Perfectly Counteracted by the Introduction of Combination Therapy (Rescue Therapy): Data from a Multicenter Real-Life Study in a Cohort of Italian Psoriatic Patients That Avoided Secukinumab Switching
Articolo
Data di Pubblicazione:
2022
Citazione:
Secukinumab Loss of Efficacy Is Perfectly Counteracted by the Introduction of Combination Therapy (Rescue Therapy): Data from a Multicenter Real-Life Study in a Cohort of Italian Psoriatic Patients That Avoided Secukinumab Switching / G. Damiani, G. Odorici, A. Pacifico, A. Morrone, R.R.Z. Conic, T. Davidson, A. Watad, P.D.M. Pigatto, D. Colombo, P. Malagoli, M. Fiore. - In: PHARMACEUTICALS. - ISSN 1424-8247. - 15:1(2022), pp. 95.1-95.11. [10.3390/ph15010095]
Abstract:
Since psoriasis (PsO) is a chronic inflammatory disease, patients may experience a drug failure also with very effective drugs (i.e., secukinumab) and, consequently, dermatologists have two therapeutic options: switching or perform a combination therapy (rescue therapy) to save the drug that had decreased its efficacy. At the moment no studies focused on combination/rescue therapy of secukinumab, so we performed a 52-weeks multicenter retrospective observational study that involved 40 subjects with plaque psoriasis that experienced a secondary failure and were treated with combination therapy (ciclosporin (n = 11), MTX (n = 15), NB-UVB (n = 7) and apremilast (n = 7)). After 16 weeks of rescue/combination therapy, PASI and a DLQI varied respectively from 8 [7.0-9.0] and 13 [12.0-15.0], to 3 [2.8-4.0] and 3 [2.0-3.3]), suggesting a significant improvement of daily functionality and quality of life. Results were maintained at 52 weeks. No side effects were experienced during the study. Secukinumab remains a safety and effective drug for PsO patients also in the IL-23 and JAK inhibitors era. The rescue therapy is a valid therapeutic option in case of secukinumab secondary failure.
Tipologia IRIS:
01 - Articolo su periodico
Keywords:
secukinumab; combination therapy; biologic multifailure; psoriasis; IL-17 inhibitors
Elenco autori:
G. Damiani, G. Odorici, A. Pacifico, A. Morrone, R.R.Z. Conic, T. Davidson, A. Watad, P.D.M. Pigatto, D. Colombo, P. Malagoli, M. Fiore
Link alla scheda completa: